BC Extra | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance  On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 21, 2019
Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

Complete response letter for Daiichi's quizartinib  Daiichi Sankyo Co. Ltd. (Tokyo:4568) said FDA issued a complete response letter for quizartinib, its candidate to treat relapsed/refractory FLT3-ITD-positive acute myelogenous leukemia (AML). In May, an FDA advisory...
BC Innovations | Apr 23, 2019
Distillery Therapeutics

The iron replacement drug Feraheme as a leukemia therapy

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Patient sample and mouse studies suggest Feraheme ferumoxytol could help treat AML with low ferroportin levels. In primary AML blasts and progenitor cells, levels of ferroportin were...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Extra | Mar 9, 2019
Clinical News

AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Dec 14, 2018
Company News

AMAG to acquire Perosphere for $50M

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) will acquire Perosphere Pharmaceuticals Inc. (Danbury, Conn.) for $50 million up front. AMAG will also assume a $12 million term loan and up to $6.2 million of Perosphere's other liabilities.The deal...
BC Extra | Sep 26, 2018
Company News

Management tracks: Merck clears path for Frazier to remain CEO

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...
BC Innovations | Aug 8, 2018
Distillery Therapeutics

Dental

INDICATION: Dental Patient sample and rat studies suggest promoting reactive oxygen species (ROS) production with Feraheme ferumoxytol and hydrogen peroxide could help treat dental caries (tooth decay). In Streptococcus mutans biofilms cultured on enamel-like hydroxyapatite,...
Items per page:
1 - 10 of 406
BC Extra | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance  On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 21, 2019
Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

Complete response letter for Daiichi's quizartinib  Daiichi Sankyo Co. Ltd. (Tokyo:4568) said FDA issued a complete response letter for quizartinib, its candidate to treat relapsed/refractory FLT3-ITD-positive acute myelogenous leukemia (AML). In May, an FDA advisory...
BC Innovations | Apr 23, 2019
Distillery Therapeutics

The iron replacement drug Feraheme as a leukemia therapy

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Patient sample and mouse studies suggest Feraheme ferumoxytol could help treat AML with low ferroportin levels. In primary AML blasts and progenitor cells, levels of ferroportin were...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Extra | Mar 9, 2019
Clinical News

AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Dec 14, 2018
Company News

AMAG to acquire Perosphere for $50M

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) will acquire Perosphere Pharmaceuticals Inc. (Danbury, Conn.) for $50 million up front. AMAG will also assume a $12 million term loan and up to $6.2 million of Perosphere's other liabilities.The deal...
BC Extra | Sep 26, 2018
Company News

Management tracks: Merck clears path for Frazier to remain CEO

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...
BC Innovations | Aug 8, 2018
Distillery Therapeutics

Dental

INDICATION: Dental Patient sample and rat studies suggest promoting reactive oxygen species (ROS) production with Feraheme ferumoxytol and hydrogen peroxide could help treat dental caries (tooth decay). In Streptococcus mutans biofilms cultured on enamel-like hydroxyapatite,...
Items per page:
1 - 10 of 406